Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 4:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 4,271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ADM Clear all

Conditions: Primary Insomnia
Interventions: zolpidem; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 21 Years to 70 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions: 3-Dimensional Conformal Radiation Therapy, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate; Radiation · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 9 Years
Enrollment: 5,377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2021
U.S. locations: 210
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more

Conditions: Breast Cancer
Interventions: Doxorubicin, Cyclophosphamide, Paclitaxel, Carboplatin, GM-CSF, Trastuzumab; Drug
Lead sponsor: Rita Sanghvi, Mehta; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Orange, California

Conditions: Type 2 Diabetes, PreDiabetes
Interventions: Project Health, Educational Video Control; Behavioral · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Noise Exposure
Interventions: Reduced noise, Normal; Other
Lead sponsor: Joshua Uffman; Other
Eligibility: Not listed
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Spinal Cord Injuries, Obesity, Cardiometabolic Syndrome
Interventions: PVA Consumer Guide, WebMD; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 70 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Miami, Florida • Dallas, Texas

Conditions: Hepatocellular Carcinoma
Interventions: Phase I dose level 1, Phase I Dose level 2, Phase I Dose level 3; Drug
Lead sponsor: Scripps Clinic Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Chronic Low Back Pain (CLBP), Insomnia
Interventions: Cognitive-behavioral therapy for insomnia (CBTi), CBTi + Savoring Meditation, CBTi + Pain Education; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Breast Cancer
Interventions: Non invasive venous ultrasound; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Auditory Processing Disorder
Interventions: Communication Counseling, Hearing Aids, Remote Microphones; Behavioral · Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 79 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8, Recurrent Pancreatic Adenocarcinoma, Oligometastatic Pancreatic Ductal Adenocarcinoma
Interventions: Chemotherapy, Stereotactic Body Radiation Therapy, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Questionnaire Administration; Drug · Radiation · Procedure + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Multiple Myeloma
Interventions: Bortezomib (VELCADE), Doxorubicin hydrochloride (DOXIL/CAELYX); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 28
States / cities: Alabaster, Alabama • Surprise, Arizona • Berkeley, California + 25 more

Conditions: Cardiovascular Diseases
Interventions: PATH Intervention, Attention Control Intervention, Physical activity tracker, Dietary education; Behavioral · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Knee Arthroscopy
Interventions: Chloroprocaine, Mepivacaine, General Anesthetics; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Ocular Hypertension
Interventions: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Multiple Myeloma
Interventions: DVD-R; Drug
Lead sponsor: Oncotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 8
States / cities: Bakersfield, California • Fresno, California • Loma Linda, California + 5 more

Conditions: Cardiovascular Disease, Diabetes, Obesity, Metabolic Syndrome, Aging
Interventions: Not listed
Lead sponsor: Tufts University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Meningococcal Infection, Group B
Interventions: 10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Coronary Artery Disease
Interventions: RXi System, Pressure Wire; Device
Lead sponsor: Acist Medical Systems; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 12
States / cities: La Jolla, California • Long Beach, California • Stanford, California + 8 more

Conditions: DOCK8 Deficiency
Interventions: Reduced-intensity hematopoietic stem cell, Fludarabine(Fludara, Berlex Laboratories), Cyclophosphamide(CTX, Cytoxan), Total Body Irradiation (TBI), Busulfan (Busulfex), Donor peripheral blood stem cell mobiliation and collection, Bone Marrow Harvest Procedure; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 4 Years to 120 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Heart Failure
Interventions: Telephone-Delivered BI, Telephone-Delivered BEI, Telephone-Delivered API; Behavioral · Other
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 21 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Paclitaxel, 5-Fluorouracil, Epirubicin, Cyclophosphamide, RAD001; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Asthma, Obesity
Interventions: Better asthma self-management and incorporation of physical activity, Asthma Education; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 21 Years to 64 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Aurora, Colorado • New York, New York

Conditions: HER2-positive Breast Cancer, Advanced Breast Cancer
Interventions: Prolonged Overnight Fasting, Moderate-Intensity Exercise, General Health Education Sessions; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Phoenix, Arizona • Miami, Florida • Boston, Massachusetts

Search by objective public record fields.

Safety and Efficacy of Chronic Hypnotic Use

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer

Evaluating a Type 2 Diabetes Prevention Program

The Effect of a Reduced Noise Environment on the Response Time of the Anesthesia Provider

Spinal Cord Injury Model Systems (SCIMS) - Education Module

TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma

Resilience Enhancement Following Sleep Treatment

Non-Invasive Imaging for Cording in Breast Cancer Patients

Hearing Aids for Veterans With Functional Hearing Difficulties

Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

Web-based Physical Activity Intervention to Promote Physical Activity

Chloroprocaine Spinal for Outpatient Knee Surgery

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma

Taste Perception and Chronic Disease Risk

Phase 1 Safety and Immunogenicity of Meningococcal Vaccine

Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement

Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency

Veterans Intensive Personalized Treatment in Heart Failure

Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer

Asthma and Obesity: Pilot Study

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer